860508P

C8 Ceramide (d18:1/8:0)

Avanti Research^™ - A Croda Brand 860508P, powder

• Sinónimos: N-octanoyl-D-erythro-sphingosine
• Fórmula empírica (notación de Hill): C₂₆H₅₁NO₃
• Número de CAS: 74713-59-0
• Peso molecular: 425.69
• UNSPSC Code: 12352211
• NACRES: NA.25

Propiedades

• form: powder
• packaging: pkg of 1 × 5 mg (860508P-5mg)
• manufacturer/tradename: Avanti Research^™ - A Croda Brand 860508P
• lipid type: sphingolipids
• shipped in: dry ice
• storage temp.: −20°C
• SMILES string: OC[C@]([H])(NC(CCCCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
• InChI: 1S/C26H51NO3/c1-3-5-7-9-10-11-12-13-14-15-16-18-19-21-25(29)24(23-28)27-26(30)22-20-17-8-6-4-2/h19,21,24-25,28-29H,3-18,20,22-23H2,1-2H3,(H,27,30)/b21-19+/t24-,25+/m0/s1
• InChI key: APDLCSPGWPLYEQ-WRBRXSDHSA-N

Descripción

General description

C8 Ceramide is a short chain ceramide and is cell permeable.

Application

C8 Ceramide (d18:1/8:0) has been used as an internal ceramide standard in electrospray ionization. It has also been used as a substrate for ceramide kinase activity assay. It is suitable for use as a substrate for galactocerebrosidase.

Biochem/physiol Actions

C8 Ceramide has anti-tumor functionality. Synthetic liposomal C8 ceramide inhibits hepatocellular carcinoma (HCC). Addition of exogenous C8 ceramide causes necrosis in hepatocytes by decreasing ATP levels and impairing mitochondrial functionality. C8 ceramide inhibition of serine palmitoyl transferase halts de novo sphingolipid biosynthesis. It also acts as chemotherapeutic agent by increasing the reactive oxygen species in lung cancer cells.

Packaging

5 mL Amber Glass Screw Cap Vial (860508P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Información de seguridad

• Storage Class: 11 - Combustible Solids